Synergy everolimus-eluting platinum chromium

Author: lfcs

August undefined, 2024

WebSynergy™ stent system comes with New laser-cut Hypotube technology having ~300 cuts over 100 mm length. It Extends into midshaft to exit port to improve pushability. … WebApr 4, 2024 · Drug-eluting coronary artery stent, non-bioabsorbable-polymer-coated A non-bioabsorbable metal tubular mesh structure covered with a non-bioabsorbable polymer and a drug coating that is designed to be implanted, via a delivery catheter, into a coronary artery (or saphenous vein graft) to maintain its patency typically in a patient with symptomatic …

Drug-eluting coronary stents: insights from preclinical and

WebThe SYNERGY BP Stent was the first FDA-approved drug-eluting stent with abluminal bioabsorbable polymer coating available in the U.S. It was designed to address the … WebWant better stent outcomes? It starts with choosing the right tool to prep the vessel. When it comes to atherectomy tool selection, the DIRO* trial showed that rotational atherectomy resulted in ... aプランニング秋田

Chocolate PTA Balloon Catheter - OTW - 3.5mm x 40mm x 135cm

WebBiotronik, Inc. Orsiro Mission Sirolimus: Cobalt chromium: PLLA: 0.014: 5: 2.25, 2.5, 2.75, 3, 3.5, 4: 9, 13, 15, 18, 22, 26, 30, 35, 40: 140: Indicated for improving coronary luminal diameter in patients, including those with diabetes mellitus, with symptomatic heart disease, stable angina, unstable angina, non–ST-segment elevation myocardial infarction or documented … WebPost-Approval Reviews (PAS) Database WebThe developments of the bioresorbable polymer-coated EES SYNERGY and the everolimus-eluting BRS ... Gao R, Han Y, Yang Y, et al. PLATINUM China: a prospective, randomized investigation of the platinum chromium everolimus-eluting stent in de novo coronary artery lesions. Catheter Cardiovasc Interv. 2015;85 ... aプランニング赤松

Premarket Approval (PMA) - Food and Drug Administration

Synergy everolimus-eluting platinum chromium

Coronary stents and vascular response to implantation: literature …

WebThis review will provide an overview of the novel platinum chromium everolimus-eluting stents that are currently available. The clinical data from major clinical trials with these … WebH ybrid coronary revascularization (HCR) was first introduced in the mid-1990s (1) as a pioneering treatment approach to multivessel coronary artery disease (CAD), hoping to bring together the "best of both worlds" .

Did you know?

Webエベロリムス溶出性プラチナクロムステント(Platinum-Chromium Everolimus-Eluting Stent [PtCr-EES]; SYNERGY® )を用いたprimary PCIが予定された、ST上昇型心筋梗塞（STEMI）患者をアスピリン非投与群（プラスグレル単剤）と12か月間の抗血小板薬2剤併用療法（DAPT）群（アスピリン＋プラスグレル）に無作為に ... WebAre Synergy stents MRI safe? Non-clinical testing has demonstrated that the SYNERGY Stent is MR Conditional for single and overlapped conditions up to 75 mm. A patient with this device can be safely scanned in a Magnetic Resonance system meeting the following conditions: Static magnetic field of 3.0 and 1.5 Tesla only.

WebSep 9, 2024 · Thin, Very Thin, or Ultrathin Strut Biodegradable or Durable Polymer-Coated Drug-Eluting Stents : 3-Year Outcomes of BIO-RESORT: Published in: JACC : cardiovascular interventions, 12(17), 1650 - 1660. Elsevier. ISSN 1936-8798. Author WebApr 10, 2024 · Synergy Everolimus-Eluting Platinum Chromium Coronary Stent System (Monorail and Over-The-Wire) Generic Name: coronary drug-eluting stent: Applicant: …

WebJul 25, 2024 · Representative histological images of the Cypher sirolimus-eluting stent (SES), Xience everolimus-eluting stent (EES) and Synergy EES in human coronary arteries. WebThe SYNERGY coronary stent is new-generation drug-eluting stents, which has a thin-strut platinum-chromium platform with everolimus in a biodegradable polymer applied to the …

WebThe SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System (SYNERGY Stent System) is a device/drug combination product consisting of a drug/polymer-coated …

WebApr 13, 2024 · For those undergoing PCI for LM disease, the IDEAL-LM (Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in patients with left main stem disease) study reported that a strategy of short 4-month DAPT (dual-antiplatelet therapy) plus a biodegradable polymer platinum-chromium everolimus-eluting stent was … 医学概論とはWebThis review will provide an overview of the novel platinum chromium everolimus-eluting stents that are currently available. The clinical data from major clinical trials with these devices will be summarized and put into perspective.Keywords: drug-eluting stent, restenosis, Promus Element, Synergy 医学書院看護師国家試験web法人サービスフルプランWebAll-Comers trial (a randomized comparison of a zotarolimus-eluting stent with an everolimus-eluting stent for percutaneous coronary intervention). J Am Coll Cardiol. 2014;63:1617–1625. 34. Serruys PW, Silber G, Garg S, et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med. 2010; 363:136–146. 35. 医学漢字マスターブック